Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | DPP4 | P27487 | 1/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | BCL3 | P20749 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | CTSS | P25774 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6394233 | 0.87 | NPC1 (0.42) | RPS6KB1RAB9ANPC1OPRM1KMT2A | |
| SCHEMBL6505267 | 0.76 | ATM (0.41) | RAB9AMAPTNPC1ATMBCL3 | |
| SCHEMBL6389539 | 0.74 | DAPK3 (0.40) | RPS6KB1ALDH1A1 | |
| SCHEMBL6387711 | 0.74 | DAPK3 (0.40) | RPS6KB1ALDH1A1 | |
| SCHEMBL6425973 | 0.74 | KMT2A (0.48) | RAB9AMAPTNPC1KMT2AATM | |
| SCHEMBL6506450 | 0.72 | CHRM1 (0.41) | RAB9ANPC1ATM | |
| SCHEMBL6428643 | 0.70 | NPC1 (0.45) | RAB9ANPC1POLBGAA | |
| SCHEMBL6389744 | 0.70 | TSHR (0.44) | RPS6KB1RAB9ANPC1KMT2APOLB | |
| SCHEMBL6386456 | 0.70 | TSHR (0.44) | RPS6KB1RAB9ANPC1KMT2APOLB | |
| SCHEMBL6508183 | 0.70 | ALDH1A1 (0.50) | MAPTDPP4KMT2APOLBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050239853-A1 | New compounds | BIOVITRUM AB (SE) | 2005-10-27 | — | — | US | claimed |
| US-20050239853-A1 | New compounds | BIOVITRUM AB (SE) | 2005-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239853-A1 | New compounds | HSD11B1, CYP11B1, HSD3B1 | RPS6KB1 635/4885RAB9A 2649/4885MAPT 3607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.